Trials / Not Yet Recruiting
Not Yet RecruitingNCT05670028
Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization
Cerebral Hemodynamic Management Based on Cerebral Autoregulation Monitoring in Acute Ischemic Stroke Patients After Endovascular Treatment: a Multicenter, Open-label, Randomized Control Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims to learn whether blood pressure (BP) guided by individualized cerebral autoregulation (CA) is safe and provides a better prognosis than a fixed target in patients with ischemic stroke after endovascular therapy. The BP of participants will be managed at least 48 hours after revascularization. Researchers will compare the CA-guided BP group with the fixed target BP group to mainly see if individualized BP could help more patients to have their neurological function improved at seven days.
Conditions
- Ischemic Stroke
- Revascularization
- Blood Pressure
- Cerebrovascular Insufficiency
- Cerebral Autoregulation
- Individuation
- Hemorrhagic Transformation Due to Acute Stroke
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hypotensive Drugs and/or Vasoactive Drugs | To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine). |
Timeline
- Start date
- 2023-06-04
- Primary completion
- 2026-01-31
- Completion
- 2026-06-04
- First posted
- 2023-01-04
- Last updated
- 2023-01-05
Source: ClinicalTrials.gov record NCT05670028. Inclusion in this directory is not an endorsement.